Starpharma Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Cheryl Maley

İcra Kurulu Başkanı

AU$475.8k

Toplam tazminat

CEO maaş yüzdesi	51.3%
CEO görev süresi	less than a year
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3yrs

Son yönetim güncellemeleri

Recent updates

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Dec 18

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Nov 22

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Mar 21

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Mar 02

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Feb 10

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Jan 20

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

Dec 28

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Dec 07

CEO Tazminat Analizi

Cheryl Maley'un ücretlendirmesi Starpharma Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$476k	AU$244k	-AU$8m

Tazminat ve Piyasa: Cheryl 'ın toplam tazminatı ($USD 297.56K ) Australian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 291.23K ).

Tazminat ve Kazançlar: Cheryl şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Cheryl Maley (55 yo)

less than a year

Görev süresi

AU$475,764

Tazminat

Mrs. Cheryl Maley, B.Sc, DipEd, MBA, GAICD, serves as Chief Executive Officer, Managing Director and Director of Starpharma Holdings Limited since January 8. 2024. She served as Non-Executive Director of C...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Cheryl Maley	CEO, MD & Director	less than a year	AU$475.76k	0.030% A$ 12.3k
Robert Thomas	Non-Executive Chairman	11yrs	AU$136.95k	0.73% A$ 298.9k
David McIntyre	Non-Executive Director	4.8yrs	AU$81.00k	0.10% A$ 41.4k
Jeff Davies	Non-Executive Director	2.7yrs	AU$75.00k	0.22% A$ 91.1k
Russell Basser	Non-Executive Director	1.8yrs	AU$77.04k	0.065% A$ 26.6k
Lynda Cheng	Independent Non-Executive Director	3.3yrs	AU$88.54k	0.041% A$ 16.7k

3.0yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SPL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 23:07
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2024/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Starpharma Holdings Limited 12 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Dennis Hulme	APP Securities Pty Ltd.
Tanushree Jain	Bell Potter
Matthijs Smith	Canaccord Genuity

Starpharma Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Non-Executive Director recently bought AU$80k worth of stock

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Recent updates

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023)

Non-Executive Director recently bought AU$80k worth of stock

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.04 loss in FY 2022)

New minor risk - Share price stability

Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer

New minor risk - Market cap size

First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023

Starpharma Holdings Limited Announces Resignation of Nigel Baade as Company Secretary

Starpharma Achieves Marketing Authorization of the Nasal Spray Product, VIRALEZETM, in Indonesia

Starpharma Holdings Limited Announces Positive AZD0466 Clinical Data Presented by Astrazeneca

Starpharma Holdings Limited Announces Management Changes

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Starpharma Holdings Limited Launches VIRALEZE in Hong Kong and Macau

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2022

Starpharma Holdings Limited Presents Compelling Data in Prostate Cancer At ESMO

Starpharma Holdings Limited Announces New Clinical Data for Dep Cabazitaxel in Prostate Cancer

Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021)

Starpharma Announces VIRALEZE Protects Against Omicron in Viral Challenge Model

Starpharma Announces SPL7013, the Antiviral Agent in VIRALEZETM Nasal Spray

Starpharma Holdings Limited Appoints Jeff Davies as Director

Starpharma Holdings Limited Announces Relaunch of VIRALEZETM in UK

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Starpharma Announces SPL7013 in Viraleze Virucidal Against Omicron

Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely

Starpharma Holdings Limited Announces Positive Interim Results from Its Ongoing Phase 2 Trial of DEP® Cabazitaxel

Starpharma Announces US Patent and Trademark Office Has Granted New Patent in Relation to DEP® Cabazitaxel

Independent Non-Executive Director recently bought AU$71k worth of stock

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020)

Starpharma Holdings Limited Announces Publication of New Data Demonstrating the Protective Efficacy of VIRALEZETM Antiviral Nasal Spray against SARS-CoV-2 Challenge in Vivo

Independent Non-Executive Deputy Chairman Peter Turvey has left the company

We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth

Starpharma Releases New Data About SPL7013

Forecast to breakeven in 2022

Starpharma Holdings Limited's VIRALEZE Antiviral Nasal Spray Registered for Sale in India

Starpharma Holdings Limited Announces VIRALEZE SPL7013 Highly Active in UK Variant of Coronavirus

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Starpharma Announces DEP HER2-Lutetium Outperforms in Human Breast Cancer Model

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Starpharma Signs DEP ADC Research Agreement with MSD

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Starpharma Holdings Limited Announces AZD0466 Clinical DEP Program Global Expansion

New 90-day high: AU$1.80

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Price target raised to AU$2.03

New 90-day high: AU$1.68

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Announces SPL7013 Shows Potent Antiviral Activity in RSV Expanding Use for Nasal Spray

Starpharma Holdings Limited announced that it has received AUD 45 million in funding

Starpharma Holdings Limited announced that it expects to receive AUD 45 million in funding

Starpharma Holdings Limited Announces That Australia Therapeutic Goods Administration Approves Expansion of the Marketing Authorisation for Vivagel® Bv

New 90-day high - AU$1.73

Analysts lower revenue estimates to AU$9.89m

Price target raised to AU$1.73

Earnings released

New 90-day high - AU$1.30